|本期目录/Table of Contents|

[1]胡守芳,吴 霞,陈与知.司美格鲁肽联合头孢哌酮钠舒巴坦治疗2型糖尿病并发肺炎的临床分析[J].中华肺部疾病杂志,2023,(01):43-46.[doi:10.3877/cma.j.issn.1674-6902.2023.01.009 ]
　Hu Shoufang,Wu Xia..Clinical analysis of Smeglutide combined with Cefoperazone Sodium Sulbactam in patients with type 2 diabetes and pneumonia[J].,2023,(01):43-46.[doi:10.3877/cma.j.issn.1674-6902.2023.01.009 ]
点击复制

司美格鲁肽联合头孢哌酮钠舒巴坦治疗2型糖尿病并发肺炎的临床分析(PDF)

《中华肺部疾病杂志》[ISSN:1006-6977/CN:61-1281/TN]

卷:
期数:
2023年01期
页码:
43-46
栏目:
论著
出版日期:
2023-02-20

文章信息/Info

Title:
Clinical analysis of Smeglutide combined with Cefoperazone Sodium Sulbactam in patients with type 2 diabetes and pneumonia
作者:
胡守芳1; 吴 霞2; 陈与知3
211800 南京,南京市浦口区中医院药剂科1、内分泌科2、呼吸科3
Author(s):
Hu Shoufang1;  Wu Xia2.
1Department of Pharmacy, 2Department of Endocrinology, Pukou Hospital of Traditional Chinese Medicine; Nanjing 211800, China
关键词:
司美格鲁肽注射液;  头孢哌酮钠舒巴坦;  2型糖尿病;  肺炎;  肺功能
Keywords:
Simaglutide injection;  Cefoperazone Sodium Sulbactam;  Type 2 diabetes;  Pneumonia;  Lung function
分类号:
R563
DOI:
10.3877/cma.j.issn.1674-6902.2023.01.009
摘要:
目的 分析司美格鲁肽注射液联合头孢哌酮钠舒巴坦对2型糖尿病并发肺炎患者治疗效果及肺功能的影响。方法 选择在2021年10月至2022年9月我院收治的2型糖尿病并发肺炎患者67例,随机分为观察组36例,对照组31例,对照组采用传统降糖联合头孢哌酮钠舒巴坦,观察组在对照组基础上采用司美格鲁肽注射液。比较两组治疗前后血糖[空腹血糖(FPG)、餐后2 h血糖(2hPG)、糖化血红蛋白(HbA1c)]、肺功能[第一秒用力呼气容积(FEV1)、用力肺活量(FVC)、最大呼气流量(PEF)FEV1/FVC]、炎症因子[白细胞介素-1(IL-1)、降钙素原(PCT)、C反应蛋白(CRP)]、临床疗效及不良反应。结果 治疗后FPG(5.41±0.78)mmol/L vs.(6.61±0.89)mmol/L、2hPG(7.22±1.15)vs.(8.86±1.25)mmol/L、HbA1c(4.56±0.71)% vs.(5.42±0.84)%、IL-11(0.21±1.86 )pg/L vs.(17.52±2.54)pg/L、PCT(0.18±0.02)ng/ml vs.( 0.41±0.06)ng/ml、CRP(8.24±1.13)mg/L vs.( 15.24±1.62)mg/L,观察组低于对照组(P<0.05),治疗后FEV1(2.58±0.35)L vs.(2.11±0.28)L、FVC(3.66±0.42)L vs.(3.18±0.46)L、PEF(36.65±4.56)L/s vs.(30.01±4.41)L/s、FEV1/FVC(71.24±6.51)% vs.(65.25±6.23)%,观察组高于对照组(P<0.05); 治疗总有效观察组29例(93.55%)高于对照组26例(72.22%)(P<0.05); 两组不良反应差异无统计学意义。结论 司美格鲁肽注射液联合头孢哌酮钠舒巴坦治疗2型糖尿病并发肺炎效果好,可控制血糖,改善肺功能,降低炎症因子水平具有临床意义。
Abstract:
Objective To analyze the effects of Smeglutide injection combined with Cefoperazone Sodium Sulbactam on the therapeutic effect and lung function of patients with type 2 diabetes complicated with pneumonia. Methods All of 67 patients with type 2 diabetes complicated with pneumonia admitted to our hospital from October 2021 to September 2022 were randomly divided into observation group(36 cases)and control group(31 cases). The control group received traditional hypoglycemic therapy combined with Cefoperazone Sodium Sulbactam, and the observation group received Smeclutide injection on the basis of the control group. Blood glucose [fasting blood glucose(FPG), 2 h postprandial blood glucose(2hPG), glycohemoglobin(HbA1c)], lung function[forced expiratory volume in the first second(FEV1), forced vital capacity(FVC), maximum expiratory flow(PEF)FEV1/FVC], inflammatory factors [interleukin-1(IL-1), Procalcitonin(PCT), C-reactive protein(CRP)], clinical efficacy and adverse reactions. Results FPG(5.41±0.78)mmol/L vs.(6.61±0.89)mmol/L, 2hPG(7.22±1.15)vs.(8.86±1.25)mmol/L, HbA1c(4.56±0.71)% vs.(5.42±0.84)%, IL-11(0.21±1.86)pg/L vs.(17.52±2.54)pg/L, PCT(0.18±0.02)ng/ml vs.(0.41±0.06)ng/ml, CRP(8.24±1.13)mg/L vs.(15.24±1.62)mg/L observation group was lower than control group(P<0.05). After treatment, FEV1(2.58±0.35)L vs.(2.11±0.28)L, FVC(3.66±0.42)L vs.(3.18±0.46)L, PEF(36.65±4.56)L/s vs.(30.01±4.41)L/s, FEV1/FVC(71.24±6.51)% vs.(65.25±6.23)% in observation group were higher than those in control group(P<0.05); 29 cases(93.55%)in the observation group were higher than 26 cases(72.22%)in the control group(P<0.05). There was no significant difference in adverse reactions between the two groups. Conclusion Smeiglutide injection combined with Cefoperazone Sodium Sulbactam is effective in the treatment of type 2 diabetes mellitus complicated with pneumonia, which can control blood sugar, improve lung function, reduce the level of inflammatory factors and reduce the incidence of adverse reactions.

参考文献/References:

1 刘 璐, 赖 倩. 雾化吸入布地奈德治疗AECOPD合并2型糖尿病患者疗效及对肺通气功能和糖代谢的影响[J/CD]. 中华肺部疾病杂志(电子版), 2021, 14(4): 427-430.
2 章江南, 赵曦乐. 甘精胰岛素控制ICU老年2型糖尿病合并重症肺炎患者血糖的疗效观察[J]. 中国现代医生, 2020, 58(31): 51-54.
3 Milionis C, Milioni SO. A brief analysis and hypotheses about the risk of COVID-19 for people with type 1 and type 2 diabetes mellitus[J]. J Diabetes Metabolic Disorders, 2020, 19(2): 2035-2039.
4 Yang H, Yue R, Zhou J, et al. Study on metabonomics of Chinese herbal medicine in the treatment of type 2 diabetes mellitus complicated with community-acquired pneumonia[J]. Medicine, 2020, 99(37): e22160.
5 王丽萍. 盐酸氨溴素注射液联合头孢哌酮钠舒巴坦治疗对2型糖尿病合并肺炎患者对肺功能的作用影响[J]. 实用糖尿病杂志, 2020, 16(6): 50-51.
6 杜桂平, 高胜男, 齐 冉, 等. 司美格鲁肽注射液治疗2型糖尿病药物经济学系统评价[J]. 中国药业, 2022, 31(16): 110-114.
7 中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2017年版)[J]. 中国实用内科杂志, 2018, 38(4): 53.
8 熊旭东, 钱义明, 陆一鸣, 等. 中西医联合治疗社区获得性肺炎专家共识(2014版)[J]. 中国中西医结合急救杂志, 2015, 22(1): 1-6.
9 Liu IC, Giap F, Mailhot-Vega RB, et al. Concomitant radiation recall dermatitis and organizing pneumonia following breast radiotherapy: A case report[J]. Case Reports Oncol, 2020, 13(2): 875-882.
10 王 斐, 陈开宁, 全会标. 64例2型糖尿病合并肺炎克雷伯菌肝脓肿患者的临床表现,病原菌药物敏感性及治疗分析[J]. 山东医药, 2021, 61(33): 88-91.
11 章江南, 赵曦乐. 甘精胰岛素控制ICU老年2型糖尿病合并重症肺炎患者血糖的疗效观察[J]. 中国现代医生, 2020, 58(31): 51-54.
13 Liu IC, Giap F, Mailhot-Vega RB, et al. Concomitant radiation recall dermatitis and organizing pneumonia following breast radiotherapy: A case report[J]. Case Reports Oncol, 2020, 13(2): 875-882.
14 Shi M, Yang A, Lau E, et al. 1071-P: Long-term renin-angiotensin system inhibitor use and risk of pneumonia and pneumonia-related death in type 2 diabetes[J]. Diabetes, 2021, 70(Supplement 1): 1071-1075.
15 王小锐, 徐贞贞. 头孢哌酮-舒巴坦与阿奇霉素联用对支原体肺炎患者伴细菌感染的临床疗效及其经济学分析[J]. 抗感染药学, 2019, 16(3): 441-443.
16 李昌盛, 戴河柳, 柴 林, 等. 胸腺肽联合头孢哌酮钠舒巴坦治疗呼吸机相关肺炎的临床研究[J]. 现代药物与临床, 2018, 33(5): 1101-1106.
17 张潇潇, 杨 杨, 赵 文, 等. 肝硬化合并细菌性肺炎的危险因素及其预后分析[J]. 中华肝脏病杂志, 2020, 28(7): 561-566.
18 Satman I, Demirci I, Haymana C, et al. Unexpectedly lower mortality rates in COVID-19 patients with and without type 2 diabetes in Istanbul[J]. Diabetes Res Clin Pract, 2021(1): 108753.
19 王聪聪, 游 娜. 司美格鲁肽联合胰岛素治疗成人隐匿性自身免疫性糖尿病1例[J]. 中国临床案例成果数据库, 2022, 4(1): E06295-E06295.
20 华炳红, 张菊云, 郑地明, 等. 司美格鲁肽对链脲佐菌素诱导的糖尿病心肌病大鼠的保护作用及其机制研究[J]. 疑难病杂志, 2022, 21(7): 21-24.
21 李 涵, 郭雯雯, 孔 雯. 胰岛素强化治疗后转换为德谷胰岛素联合司美格鲁肽和二甲双胍改善血糖控制1例[J]. 中国临床案例成果数据库, 2022, 4(1): E06167-E06167.
22 卓莉莉, 张秋玲, 王 婧, 等. 司美格鲁肽改善糖尿病合并代谢综合征1例[J]. 中国临床案例成果数据库, 2022, 4(1): E06286-E06286.
23 Onishi K, Baba N, Nagai S, et al. Development of a hyperosmolar-hyperglycemic state and possible fulminant type 1 diabetes mellitus during the treatment of a case of adenocarcinoma of the lung and interstitial pneumonia[J]. Diabetol Int, 2022, 13(3): 580-583.
24 Li D, Liu H, Wang Y, et al. Clinical features of 30 cases with novel coronavirus pneumonia[J]. Chin J Infect Dis, 2020, 38(00): E018-E018.
25 郭艳琼, 彭 晶, 李庆德, 等. 基于OpenFDA数据挖掘和分析司美格鲁肽的不良事件报告信号[J]. 中国药师, 2022, 25(3): 475-478.
26 何晓东, 李 琴, 刘慧敏, 等. 司美格鲁肽周制剂治疗成人超重和肥胖有效性与安全性的系统评价和Meta分析[J]. 中国医院药学杂志, 2022, 42(16): 1709-1715.
27 赵 楠, 刘 文, 杜 娟, 等. 胰岛素强化治疗后转换为司美格鲁肽治疗新诊断2型糖尿病1例[J]. 中国临床案例成果数据库, 2022, 4(1): E06294-E06294.
28 张 湛, 王晓兵, 凌 萌, 等. 头孢哌酮钠舒巴坦钠联合替加环素治疗ICU重度腹腔感染的疗效[J]. 中华医院感染学杂志, 202, 30(17): 2666-2670.
29 王 宇. 头孢哌酮舒巴坦对慢性心力衰竭伴肺部感染患者细菌清除率及血气指标的影响[J]. 中国校医, 2020, 34(4): 304-305.
30 尚 丹. 美罗培南与头孢哌酮钠舒巴坦治疗老年肺部感染患者的临床效果[J]. 中国医药指南, 2021, 19(14): 30-31.

备注/Memo

备注/Memo:
基金项目: 江苏省卫生健康委科研课题(H20180582)
通信作者: 吴 霞, Email: 1378484021@qq.com
更新日期/Last Update: 2023-02-20